Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gabriel F. Barrio-Echavarria"'
Autor:
Iván A. Aréchiga, Gabriel F. Barrio-Echavarria, Aldo A. Rodríguez-Menchaca, Eloy G. Moreno-Galindo, Niels Decher, Martin Tristani-Firouzi, José A. Sánchez-Chapula, Ricardo A. Navarro-Polanco
Publikováno v:
Journal of Pharmacological Sciences, Vol 108, Iss 1, Pp 49-55 (2008)
Kv1.5 is considered to be a potential molecular target for treatment of atrial fibrillation or flutter. Disopyramide is widely used in the treatment of atrial flutter and/or atrial fibrillation. The present study was undertaken to characterize the ef
Externí odkaz:
https://doaj.org/article/ead7d2eb701d42ad956e37d6f374ed81
Autor:
Martin Tristani-Firouzi, José C. Vásquez, Ricardo A. Navarro-Polanco, José A. Sánchez-Chapula, Niels Decher, Gabriel F. Barrio-Echavarria, Frank B. Sachse, Eloy G. Moreno-Galindo
Publikováno v:
Molecular Pharmacology. 77:751-758
The endocannabinoid, N-arachidonoylethanolamine (anandamide; AEA) is known to interact with voltage-gated K(+) (Kv) channels in a cannabinoid receptor-independent manner. AEA modulates the functional properties of Kv channels, converting channels wit
Autor:
Eloy G. Moreno-Galindo, Niels Decher, Ricardo A. Navarro-Polanco, José A. Sánchez-Chapula, Aldo A. Rodríguez-Menchaca, Iván A. Aréchiga, Martin Tristani-Firouzi, Gabriel F. Barrio-Echavarria
Publikováno v:
Journal of Pharmacological Sciences, Vol 108, Iss 1, Pp 49-55 (2008)
Kv1.5 is considered to be a potential molecular target for treatment of atrial fibrillation or flutter. Disopyramide is widely used in the treatment of atrial flutter and/or atrial fibrillation. The present study was undertaken to characterize the ef